Design of clinical studies: adaptive randomization and progression-free survival (PFS) as an endpoint in clinical studies of advanced non-small cell lung cancer (NSCLC)

Int J Clin Pharmacol Ther. 2013 Jan;51(1):84-6. doi: 10.5414/cpp51084.
No abstract available

Publication types

  • Meta-Analysis

MeSH terms

  • Bayes Theorem
  • Carcinoma, Non-Small-Cell Lung / epidemiology*
  • Carcinoma, Non-Small-Cell Lung / therapy*
  • Disease-Free Survival
  • Humans
  • Lung Neoplasms / epidemiology*
  • Lung Neoplasms / therapy*
  • Quality of Life
  • Randomized Controlled Trials as Topic / methods*
  • Research Design*
  • Sample Size